suturing the tracheal cartilage to sternoclavicular joint. The complication rate and PCF rate were analyzed.
Method:
A retrospective chart review of 53 patients treated from 2005 to 2008 with CRT for stage 3 (6%) or stage 4 (94%) OPSCC at a tertiary referral center. Variables reviewed included type of CRT, PET-CT results, and smoking history. Outcomes evaluated included patterns of recurrence, survival, and progression free survival (PFS).
Results: Overall PFS rate was 77% at 3 years. The first post-treatment PET-CT obtained a median of 2.3 months after CRT was normal in 32 patients, however 5 patients ultimately relapsed. Sixteen patients had elevated FDG uptake of which 3 recurred. The result of the first PET-CT was not significantly associated with recurrence (P = .2988). The second posttreatment PET-CT, obtained a median of 8.6 months after CRT, was normal in 28 patients, of which only one relapsed. Four out of 12 patients with abnormal scans recurred. A normal delayed PET-CT predicted the absence of disease (P = .0211).
Conclusion:
A normal PET-CT early after CRT for OPSCC did not reflect the absence of disease. A normal PET-CT 6 to 8 months after treatment predicted good control of disease. The optimal time for PET-CT to demonstrate prognostic value may be 6 to 8 months after completion of CRT.
Head and Neck Surgery Proliferative Verrucous Leukoplakia: Rare but Lethal
Wesley M. Abadie, MD (presenter); Cecelia Schmalbach, MD Objective: Proliferative verrucous leukoplakia (PVL) is a rare, recalcitrant, and lethal form of leukoplakia necessitating special attention. The purpose of this review is to further educate the otolaryngology community and to characterize the risk factors, clinical course, and optimal treatment for this highly aggressive, premalignant oral lesion.
Method: A retrospective review was performed on all PVL cases treated at WMHC from 1985 to 2010. This data was pooled with additional PVL cases identified following a systemic review of the English-language literature. Only articles addressing epidemiology, histopathology, treatment outcomes, and malignant progression were pooled and analyzed with our data.
Results: A total of 243 PVL cases met inclusion criteria. The mean patient age was 66 years. The majority of patients were female (72%) and nonsmokers (64.6%). HPV has not been found to be a risk factor. The average length of follow-up was 5.5 years, with an average of 10.7 biopsies per patient during this period. PVL exhibits histopathologic features along a progressive spectrum, evolving from leukoplakia and verrucous hyperplasia eventually to invasive carcinoma. Definitive treatment was rarely successful, with PVL recurrence rates reaching 88%. Rate of progression to verrucous carcinoma or oral squamous cell carcinoma was high (63.6%).
Conclusion: PVL is a rare but recalcitrant form of leukoplakia with a malignant transformation rate reaching 64%. PVL warrants high clinical suspicion, to include a lifetime of close follow-up by a physician well versed in oral carcinoma. Repeat biopsy should be considered an integral part of this routine follow-up.
Head and Neck Surgery PTH Level, Gland Radioactivity, and Gland Weight in MIRP
Evan Robert Moore, MD (presenter); Horace Spencer; Brendan C. Stack, MD; Donald Bodenner, MD, PhD Objective: Better understand the relationships of parathyroid hormone production (PTH), adenoma gamma counts, and adenoma weight in patients undergoing minimally invasive parathyroidectomy for primary hyperparathyroidism due to single gland disease.
Method: A retrospective review of 68 patients that had minimally invasive parathyroid surgery for single gland disease. All patients underwent intraoperative PTH monitoring as well
